Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
|Videos|October 6, 2017
Dr. Hensing Discusses Studies in Stage III NSCLC
Author(s)Thomas A. Hensing, MD
Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non-small cell lung cancer (NSCLC).
Advertisement
Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non—small cell lung cancer (NSCLC).
Hensing says that the most exciting prospective study in stage III NSCLC is the PACIFIC trial, which evaluated durvalumab (Imfinzi) following concurrent chemoradiation.
The progression-free survival Kaplan-Meier curve in this trial was the first time an improvement in outcome was observed for patients with stage III disease.
Advertisement
Related to this article
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
4
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
5